Meanwhile, Eli Lilly's Zepbound injection has gained traction, prompting both firms to race toward more convenient ...

The Danish drugmaker, which makes Ozempic and Wegovy, has seen its stock tumble as competition in the weight-loss drug market ...

Wegovy-maker Novo Nordisk said on Friday its CEO Lars Fruergaard Jorgensen will step down over concerns the company is losing ...

Eli Lilly (NYSE:LLY) recently announced the impressive results of its SURMOUNT-5 trial, highlighting Zepbound's efficacy over ...

Wegovy-maker Novo Nordisk ousted CEO Lars Fruergaard Jorgensen on Friday over concerns the company is losing its first-mover ...

Lars Fruergaard Jørgensen, who has led the pharmaceutical giant since 2017, joined the firm in 1991.View on euronews ...

Novo Nordisk CEO's ouster signals stiff competition in the obesity market, getting dominated by Eli Lilly, with Roche, ...

As Novo Nordisk's share price drops, CEO Lars Fruergaard Jorgensen steps down. The company aims to maintain its lead in the competitive weight-loss drug market.

Novo Nordisk CEO Lars Fruergaard Jorgensen will step down amidst growing concerns about the company's competitive position in ...

Novo’s shares have plunged since hitting a record-high in June last year as competition, particularly from Eli Lilly, makes inroads into its market share and as its pipeline of new drugs has ...

The company behind the weight loss sensation that transformed bodies and bank accounts across America just showed its own CEO ...

The boss of the drugs giant behind Ozempic has quit after falling behind in the global race to develop weight-loss medication ...